Dapagliflozin, as Add-on Therapy in Type 2 Diabetes Patients, Is Associated With a Reduction in Albuminuria and Serum Transaminase Levels

INTRODUCTION: SGLT-2 inhibitors are shown to be nephroprotective, slowing progression of nonalcoholic steatohepatitis (NASH) in addition to improving glycemic control in patients with type 2 diabetes (T2D). To date, no real-life clinical data is available on the effect of SGLT-2 inhibitors on urine...

Descripción completa

Detalles Bibliográficos
Autores principales: Benjamin, Silas, Ramanjaneya, Manjunath, Butler, Alexandra E., Janjua, Imran, Paramba, Firjeeth, Palaki, Jafer, Kubaisi, Aisha Al, Chandra, Prem, Abdalhakam, Ibrahem, Massodi, Nasseer Ahmad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Clinical Diabetes and Healthcare
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012067/
https://www.ncbi.nlm.nih.gov/pubmed/36994321
http://dx.doi.org/10.3389/fcdhc.2021.733693

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012067/
https://www.ncbi.nlm.nih.gov/pubmed/36994321
http://dx.doi.org/10.3389/fcdhc.2021.733693

Ejemplares similares